Table 2.
Participants’ demographics and treatment characteristics
| Characteristics | Participants (N=292) |
|---|---|
| Age, years, mean (SD) | 48.5 (15.1) |
| Age at diagnosis, years, mean (SD) | 35.8 (18.7) |
| Duration of psoriasis, years, mean (SD) | 12.6 (16.8) |
| Duration of psoriasis, years, n (%) | |
| <10 | 173 (59.2) |
| 10–<20 | 42 (14.4) |
| ≥20 | 77 (26.4) |
| Female, n (%) | 148 (50.7) |
| Geographical location, n (%) | |
| England | 235 (80.5) |
| Wales | 24 (8.2) |
| Scotland | 29 (9.9) |
| Northern Ireland | 4 (1.4) |
| Nails affected by psoriasis, n (%) | 133 (45.5) |
| Scalp affected by psoriasis, n (%) | 235 (80.5) |
| Diagnosed with psoriatic arthritis, n (%) | 102 (34.9) |
| Previous exposure to biologic therapy, n (%) | 75 (25.7) |
| Palm areas affected by psoriasis, mean (SD) | 9.4 (7.2) |
| Total palm areas affected by psoriasis, n (%) | |
| 3–<5 | 50 (17.1) |
| 5–<10 | 150 (51.4) |
| 10–<15 | 51 (17.5) |
| ≥15 | 41 (14.0) |
| DLQI score, mean (SD) | 10.5 (6.6) |
| Total DLQI score, n (%) | |
| 0–1 | 8 (2.7) |
| 2–5 | 70 (24.0) |
| 6–10 | 88 (30.1) |
| 11–20 | 95 (32.5) |
| 21–30 | 31 (10.6) |
| Worst aspect of psoriasis to live with, n (%) | |
| Itching | 145 (49.7) |
| Location of psoriasis | 67 (22.9) |
| Size of rash from psoriasis | 42 (14.4) |
| Pain or discomfort | 35 (12.0) |
| Poor sleep | 3 (1.0) |
| Current treatment being received, n (%) | |
| Orally taken tablet/capsule | 80 (27.4) |
| Subcutaneous injection | 38 (13.0) |
| Intravenous infusion | 12 (4.1) |
| Cream applied to the skin | 249 (85.3) |
| Satisfaction with current treatment, n (%) | |
| Very satisfied | 23 (7.9) |
| Somewhat satisfied | 98 (33.6) |
| Neutral or not sure | 76 (26.0) |
| Somewhat dissatisfied | 63 (21.6) |
| Very dissatisfied | 32 (11.0) |
Abbreviations: DLQI, Dermatology Life Quality Index; SD, standard deviation.